Junshi strikes deal with startup for cancer assets
Shanghai-based Junshi Biosciences has quietly partnered with Wigen Biomedicine for the global rights to develop, manufacture, and commercialize four of its innovative, small molecule cancer drug assets.
Junshi boosts its cancer pipeline in this deal, receiving one of WJ1024 or WJ1075, XPO-1 inhibitors with potential in a number of blood cancers and solid tumors; WJ05129, an Aurora A inhibitor that can be used to treat small cell lung cancer and triple negative breast cancer; and two EGFR inhibitors in APL1898 and WJ13404.
The Shanghai-based startup will split its ownership of these therapies with Junshi as the two companies work together on pre-clinical research of the molecules. Wigen will receive $5.3 million in upfront payment and milestone payments of $64 million depending on R&D and commercialization progress, in addition to 50% of net profits.
Junshi boosts its cancer pipeline in this deal, receiving one of WJ1024 or WJ1075, XPO-1 inhibitors with potential in a number of blood cancers and solid tumors; WJ05129, an Aurora A inhibitor that can be used to treat small cell lung cancer and triple negative breast cancer; and two EGFR inhibitors in APL1898 and WJ13404.
The Shanghai-based startup will split its ownership of these therapies with Junshi as the two companies work together on pre-clinical research of the molecules. Wigen will receive $5.3 million in upfront payment and milestone payments of $64 million depending on R&D and commercialization progress, in addition to 50% of net profits.
.png)
No hay comentarios:
Publicar un comentario